Loading
AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer.
AVZO-023 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Avenzo Therapeutics, Inc., in metastatic cancer. Described in the registry record as a avzo-023 is an oral selective cdk4 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a avzo-023 is an oral selective cdk4 inhibitor; the trial entries below carry the sponsor's wording. Connects to CDK4/6.
1.AVZO-023 slips into a pocket on CDK4/6.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVZO-023" OR ABSTRACT:"AVZO-023") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVZO-023, not a curated reading list.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.